Eisbach Bio

Description: Eisbach Bio develops first-in-class cancer drugs targeting genetic vulnerabilities, spun out of Munich's Biomedical Center in 2019.

Country: Germany

Based in: Munich

Founded: 2019

Funding Stage: Pre-Seed

Tags: ['Biotechnology', 'Pharmaceutical', 'Manufacturing']

Categories

Add insights to your inbox

We’ll send you content you’ll want to read- and put to use.

Details about how we process your information are available in our Privacy Policy.